Last $66.47 USD
Change Today -0.20 / -0.30%
Volume 527.2K
STJ On Other Exchanges
New York
As of 8:04 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

Saint Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

l implantable device is designed to help physicians monitor for abnormal cardiac rhythms. NMD The company’s NMD product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. Its commercialized neurostimulation therapies include spinal cord stimulation (SCS) for the treatment of chronic pain, deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease and peripheral nerve stimulation (PNS) for the treatment of chronic migraine headache. A neurostimulation system consists of four components, including a pulse generator that produces the electrical current and is implanted under the patient's skin; implanted leads that carry the electrical impulses to the targeted nerve sites; an external patient remote control that enables the patient to control his or her therapy within prescribed ranges; and an external clinician programmer that is used to program the implant with individualized therapy for the patient. Neurostimulation for the treatment of chronic pain involves delivering low-level electrical impulses through an implanted device (sometimes referred to as a ‘pacemaker for pain’) directly to the spinal cord or peripheral nerves. This stimulation interferes with the transmission of pain signals to the brain and inhibits or blocks the sensation of pain felt by the patient. The patient's sensation of pain is replaced with a sensation called paresthesia, which is described as a tingling or massaging sensation. Neurostimulation for chronic pain is used to manage sharp, intense, and constant pain arising from nerve damage or nervous system disorders referred to as neuropathic pain. The company offers a range of neurostimulation systems for chronic pain, including rechargeable and primary cell implantable pulse generators (IPGs). It markets two SCS neurostimulation product platforms worldwide, such as the Eon IPG family, which includes rechargeable and primary cell battery models, and the Genesis primary cell IPG systems. The Eon family of IPGs includes the Eon, Eon Mini, and EonC IPG. The Eon rechargeable IPG (FDA and European CE Mark approvals) is a 16-contact IPG with a high capacity battery. It offers a range of options to help the clinician maximize success in managing chronic pain. The Eon IPG provides improved longevity between recharges, allowing patients added flexibility in their recharging schedule. It is FDA approved to operate approximately 24 hours between recharges after 10 years of use at high settings. The Eon Mini rechargeable IPG (FDA approval and European CE Mark approval) is a smaller 16-contact IPG on the market enabling alternative placement options, which helps clinicians treat various patients. Like the Eon IPG, it is FDA approved to operate at least 24 hours between recharges after 10 years of use at high settings - a long battery life for its small size. The Eon Mini IPG is suited for patients with smaller body mass and low to high power requirements. The Genesis IPG (FDA and European CE Mark approvals) offers a high battery capacity-to-size ratio and flexibility in addressing various pain patterns. Primary cell IPGs, such as Genesis, are suited for patients with relatively simple pain or modest power requirements and for patients who would have difficulty managing a rechargeable system. Each of the company’s SCS systems works with a corresponding patient remote control. The remote control allows patients to control their pain by adjusting therapy intensity and therapy location with simple adjustments. The controllers work by placing a small antenna through the IPG site to adjust the patient's prescribed stimulation parameters. In combination with the company’s range of implanted pulse generators, the company markets various leads, which are intended to give clinicians the flexibility to meet a range of patient needs. Its leads could be divided into three categories, such as percutaneous leads, paddle leads, and perc-paddle leads. The company’s percutaneous leads consist of the 8-contact Octrode and 4-contact Quattrode lead designs. Its paddle lead offering consists of the Lam


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $66.47 USD -0.20

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $13.17 USD +0.04
Coloplast A/S kr515.50 DKK -5.50
Smith & Nephew PLC 1,173 GBp +84.00
Terumo Corp ¥2,830 JPY -12.00
Zimmer Holdings Inc $114.17 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation STJ Industry Range
Price/Earnings 22.0x
Price/Sales 3.4x
Price/Book 4.6x
Price/Cash Flow 21.6x
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at